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CURRENT OPINION
Traditional Anticoagulants and Hair Loss: A Role for Direct Oral
Anticoagulants? A Review of the Literature
Magdalena M. Watras1 • Jignesh P. Patel2,3 • Roopen Arya2
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Hair loss is associated with the anticoagulants
heparin and warfarin. With the recent availability of direct
oral anticoagulants (DOACs) it is of clinical interest to
know if they are implicated with hair loss and/or whether
they could be successfully prescribed for patients who
suffer from coumarin- or heparin-related alopecia. Initially
reports of heparin- and coumarin-associated alopecia
available through PubMed and Medline were explored in
order to establish the cause of this side effect. Currently
there is a lack of unanimity on why anticoagulants cause
alopecia. However, timing and presentation strongly sug-
gest that telogen effluvium is part of the process. The
observation that both heparins and coumarins cause a
similar pattern of hair loss suggests a shared mechanism
related to anticoagulant activity. To date, the World Health
Organization has received 405 reports of DOAC-associated
alopecia through their pharmacovigilance database
VigiBase. Additionally, real world registry data describes
an alopecia incidence of 4.4 per 100 patient years in
patients prescribed rivaroxaban and dabigatran. Further
widespread clinical experience is required to ascertain if
this is true, but early indications suggest that DOACs are
implicated in hair loss and will not provide a suitable al-
ternative for patients suffering from alopecia related to
traditional anticoagulants.
Key Points
Traditional anticoagulants are known to cause hair
loss and the mechanism is likely to be related to their
therapeutic activity.
Early experience with direct oral anticoagulants
suggests that they are also implicated in this side
effect and therefore do not offer an alternative to
patients experiencing alopecia due to treatment with
coumarins or heparins.
1 Background
Many drugs are associated with hair loss but rarely is the
causation as certain as that seen with cancer chemotherapy
or sodium valproate [1]. Hair loss, or alopecia, associated
with drug use is often considered an idiosyncratic adverse
effect of uncertain mechanism. Reports of alopecia linked
to the use of anticoagulants date back to shortly after their
clinical use became widespread and began to emerge in the
1950s, first with unfractionated heparin and then with oral
coumarins, with reported incidences of 54–66 and
30–40 %, respectively [2, 3]. Since then, all anticoagulants
have been implicated in causing alopecia to some extent.
Table 1 lists the cases and reports which have been pub-
lished in the literature to date. Despite the high reported
incidence of anticoagulant-related alopecia and the volume
of anticoagulant use, the database of the World Health
Organization (WHO)–Uppsala Monitoring Centre (UMC)
VigiBase has on record 877 cases of alopecia related to
warfarin, 105 to acenocoumarol and 2 to phenindione [4].
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For the heparins, including the low molecular weight
heparins, 134 cases are recorded in total. This discrepancy
between the early reported incidences and the reports on
file at VigiBase suggests either that alopecia is much less
prevalent than initially reported or, more likely, that it is so
common that prescribers judge it unnecessary to report,
particularly as alopecia is listed as a side effect in the
Summary of Product Characteristics for both heparins and
warfarin [5, 6].
The recent availability of direct oral anticoagulants
(DOACs) in clinical practice is leading a paradigm shift in
how patients are managed for the acute and long-term
treatment of venous thromboembolism and for stroke
prophylaxis in the context of atrial fibrillation. The DOACs
exert their pharmacological effect on a single coagulation
protein in the coagulation cascade and are reported to have
less drug-drug and no drug-food interactions compared to
the oral courmarins and thus are considered to have pre-
dictable pharmacokinetic profiles. Interested readers are
referred to Heidbuchel et al. [7] for more details. Given
their widespread use in daily practice, it is of interest to
know if the DOACs are likely to be implicated in the
occurrence of the adverse effect alopecia and thus whether
or not they could be successfully prescribed for patients
who suffer from coumarin- or heparin-related alopecia.
In order to answer this question, an understanding of
hair growth and loss is required.
2 Hair Growth and Hair Loss
Hair growth is a cyclical process which consists of three
stages. It begins with the growth or anagen phase,
during which there is vigorous mitotic activity in the
Table 1 Published case reports linking increase in hair loss with anticoagulants (presented in chronological order)
Age
(years)
Sex Drug Indication for anticoagulation Treatment duration until
report of hair loss
Year Refs.
2 F Warfarin Accidental ingestion 2.5 weeks 1957 [9]
43 M Heparin Thrombophebitis 2 months 1965 [7]
6 M Warfarin Chronic accidental ingestion Unknown 1965 [7]
62 F Warfarin Mitral valve replacement 10 years 1988 [10]
55 M Warfarin Aortic valve replacement 13 years 1988 [10]
65 F Warfarin Mitral valve replacement 1.5 years 1988 [10]
35 M Warfarin Aortic valve replacement 5 years 1993 [11]
57 F Warfarin Cardiogenic brain embolism 2 months 1995 [11]
49 F Warfarin Systemic lupus erythematosus 2 months 1995 [12]
9 F Dalteparin Sinus venous thrombosis 2.5 months 2000 [16]
62 M Acenocoumarol Post MI to prevent aneurysm 2 months 2000 [15]
65 M Acenocoumarol Cardioembolic stroke 2 months 2000 [15]
60 F Acenocoumarol Valve prosthesis 16 months 2000 [15]
69 F Dalteparin Prevention of extracorporeal clotting in
haemodialysis
1.5–3 months 2001 [15]
75 F Dalteparin Prevention of extracorporeal clotting in
haemodialysis
1.5–3 months 2001 [17]
59 F Dalteparin Prevention of extracorporeal clotting in
haemodialysis
1.5–3 months 2001 [17]
74 F Dalteparin Prevention of extracorporeal clotting in
haemodialysis
1.5–3 months 2001 [17]
66 M Tinzaparin Prevention of extracorporeal clotting in
haemodialysis
3 months 2003 [18]
34 F Enoxaparin for 3 weeks then
warfarin
Cerebral venous thrombosis 3 weeks from treatment
start
2006 [19]
22 F Enoxaparin for 3 weeks then
warfarin
Cerebral venous thrombosis 3 weeks from treatment
start
2006 [19]
52 F Enoxaparin for 3 weeks then
warfarin
Cerebral venous thrombosis 3 weeks from treatment
start
2006 [19]
70 F Warfarin Deep vein thrombosis ‘‘soon’’ 2008 [13]
25 M Warfarin Pulmonary embolism 1 month 2010 [14]
M. M. Watras et al.
hair matrix (part of the hair follicle that produces pig-
mented cells that make up the structure of the hair) and
the hair grows continuously. This phase lasts between a
few months and a few years and the duration of the
phase dictates the length of the hair. This is followed by
a short cessation or catagen phase during which the hair
matrix regressively changes as its cells undergo apop-
tosis. As the hair stops growing, the follicle shortens
and the mature hair moves upwards toward the epider-
mis where it enters the rest or telogen phase [8]. During
this resting period, which lasts around 3 months, the
hair awaits shedding through either friction such as
combing or shampooing or through displacement by
newly growing hair underneath. At any given time
approximately 85–90 % of hair on the scalp is in the
anagen phase, 9–14 % is in the telogen phase, and only
1 % is in the catagen phase. On average around 30–100
hairs will enter each phase per day and approximately
that number will be shed. However, the length of each
phase and the proportion of hair in each stage varies
widely amongst individuals [9, 10].
Hair loss can be exacerbated by drugs via two different
mechanisms, both affecting the hair in the anagen phase.
Cancer chemotherapy, for example, causes anagen efflu-
vium where the cytotoxic agent abruptly arrests hair
growth through its antimitotic action. The onset is rapid
and as a result anagen hairs fall out in a dystrophic and
brittle form within days to weeks of drug exposure. This
leads to clinically significant alopecia [8].
The second mechanism, telogen effluvium, is a result
of anagen hair shifting into the catagen phase prema-
turely. When this occurs, the proportion of hair shafts in
the resting phase ready to vacate increases, which in turn
engenders excessive hair loss. Telogen effluvium can be
precipitated by fever, surgery, haemorrhage, childbirth or
‘crash’ dieting, as well as by drugs [11]. Whether the
resulting alopecia is noticeable depends on certain factors:
the individual’s baseline daily hair loss, how much scalp
hair they have and whether or not the increased transition
into the catagen phase occurs in a continuous or inter-
mittent manner. The effects are usually visible at around
2–4 months after exposure to the triggering factor.
However, telogen effluvium is a dynamic process during
which hair loss usually occurs because of emerging hair
pushing out hair in the telogen phase. Therefore, if the
follicles enter the telogen stage asynchronously as a
consequence of chronic exposure to the drug or some
other insult, it may take months to years before hair loss
is obvious to the patient and alopecia becomes clinically
significant [8, 11].
3 Traditional Anticoagulants and Hair Loss
Traditional anticoagulants are thought to cause hair loss
through telogen effluvium, and so alopecia associated with
heparins and coumarins may take time to become apparent.
In fact, telogen effluvium can frequently go unnoticed, as
often hair falling out is due to the re-growth of new hair
underneath. Hence, an increase in shedding might not
always present as clinically significant alopecia. The
latency period between exposure to a drug trigger and
increase in hair loss may additionally explain why the
phenomenon is under-reported. Finally, there is great
interindividual variability in baseline daily hair loss and in
density of telogen scalp hair, which dictates whether the
increase in rate of loss will lead to cosmetically compro-
mising alopecia [8]. This represents a further complicating
factor in determining the extent to which anticoagulants
cause an increase in hair loss and alopecia.
A literature search of Embase (1947 to present) and
Medline (1946 to present) using terms ‘alopecia’ or ‘hair
loss’ in conjunction with ‘heparin’, ‘warfarin’, ‘aceno-
coumarol’, ‘phenindione’, ‘dalteparin’, ‘enoxaparin’ and
‘tinazparin’ was conducted on the 15 July 2015 and yielded
12 case reports. The first report describes a 2-year-old girl
who accidently ingested an unknown amount of the rat
poison ‘d-con’, the active ingredient of which is warfarin.
Her mother first noticed hair loss 17 days from the accident
which peaked at day 21. Her hair started re-growing after
31 days [12]. Accidental warfarin ingestion is also reported
by Rook [10]: a 6-year-old boy was noted to lose over
50 % of his hair during a 6-month period when he was
often observed to play with soil on a farm which used
warfarin as rat poison. Rook also describes a more typical
case of a 43-year-old man who complained of severe
alopecia 3 months after his heparin treatment for throm-
bophlebitis. Three different cases of alopecia associated
with warfarin use post-valve replacement are reported by
Umlas and Herken [13] and one by Al-Ibrahim et al. [14]: a
55-year-old man who complained of an increase in hair
shedding 13 years after first taking warfarin, a 65-year-old
woman with alopecia appearing 1.5 years into treatment
with warfarin and persisting for the duration it is prescribed
(14 years), and a 62-year-old woman who only noticed hair
loss after 10 years on chronic warfarin therapy; in the latter
case, however, the alopecia resolved on discontinuation of
anticoagulation and re-appeared on re-challenge [14]. In
the case described by Al-Ibrahim et al. [14] the patient
presented with alopecia that affected his beard, scalp and
moustache 5 years into treatment with warfarin. Two
reports were published in the 1990s, a 57-year-old female
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treated with warfarin for cardiogenic brain embolism and a
49-year-old female, positive for lupus anticoagulant and
therefore started on warfarin therapy. Both of them com-
plained of increased hair shedding 2 months into treatment
[15]. In recent years there have been only two reports of
warfarin-associated alopecia: In 2008 a 70-year-old female
anticoagulated for deep vein thrombosis (7 mg/day, no
international normalized ratio (INR) target reported) was
described to lose patches of previously thick hair soon after
commencing treatment [16]. Nakamizo and colleagues [17]
describe a 25-year-old man who underwent several cycles
of chemotherapy and as a result lost hair all over his body,
which then fully regrew 5 months after finishing treatment.
He was then treated with warfarin for pulmonary embolism
and 1 month into anticoagulant treatment complained of
severe diffuse hair loss. The authors speculate that alopecia
occurs within 1 month of treatment with warfarin due to an
increase in scalp telogen hair post-chemotherapy.
There are three reports of acenocoumarol-associated
alopecia published in the literature. In all three cases
increase in hair loss is reported within months of starting
treatment and it persists for the duration of treatment [18].
The first report of low molecular weight heparin-asso-
ciated alopecia was in 2000, where a 9-year-old girl who
was treated with dalteparin (100 U/kg) for sinus vein
thrombosis noticed extensive hair loss 10 weeks into the
treatment. She was on no other medication that could lead
to hair loss and it improved 2 weeks after treatment ces-
sation [19]. In 2001, another report was published
describing four cases of dalteparin-associated alopecia.
Women aged between 59 and 75 year were anticoagulated
with dalteparin (80 IU/kg) for prevention of extracorporeal
clotting in haemodialysis. They noticed ‘‘hair coming out
in handfuls’’ between 6 weeks and 3 months from starting
treatment. When the anticoagulation regimen was changed
to citrate, hair loss stopped and in one patient that was re-
challenged with dalteparin, it re-appeared [20]. Tinzaparin
has also been linked to diffuse alopecia in a 66-year-old
man who had been on enoxaparin for 9 months and then
was switched to tinzaparin for 3 months for prevention of
extracorporeal blood clotting. Interestingly, hair loss only
occurred with tinzaparin and not enoxaparin. A biopsy of
the alopecia area showed ‘‘atrophic hair follicle in the
papillary dermis and widened follicles filled with keratin
fragments’’ [21]. Wang and colleagues [22], however,
describe three cases of females (aged 22–52 years) treated
with enoxaparin (1 mg/kg twice a day) and then with
warfarin for sinus vein thrombosis who noticed a signifi-
cant increase in hair loss 3 weeks after commencing
treatment with enoxaparin. Dermatologists were consulted
and diagnosed telogen effluvium. Interestingly, alopecia
ceased during treatment with warfarin (INR target of 2).
All three cases were rated 6 on the Naranjo Adverse Drug
Reaction (ADR) probability score and therefore enoxaparin
was deemed to be the cause of the alopecia [22].
The published case reports suggest that alopecia is
reversible on cessation of treatment and reappears on re-
challenge [13, 20]. For warfarin, hair loss is reported to
begin after 3 months of treatment, but the time range of
onset reported is wide: 2 months to 13 years. Similarly,
with heparins, the time of onset is wide, with the average
time of onset similar to that reported with warfarin. Despite
the fact that spontaneously shed hair was not examined in
any of the reported cases, the timing and presentation of
hair loss strongly suggests telogen effluvium to be the
mechanism.
Age and gender do not affect susceptibility to antico-
agulant-induced telogen effluvium [10]. However, there are
more published reports in women. This is possibly because
of men attributing hair loss to male-pattern baldness.
Additionally, females might aggravate the shedding of the
resting hair resulting from telogen effluvium by frequent
grooming, and therefore increase the rate of loss to a level
that produces obvious alopecia.
There is a lack of unanimity over the influence of dose
and treatment duration with anticoagulants and the rela-
tionship with alopecia. Case reports that implicate oral
coumarins in causing telogen effluvium state the dose of
the drug that the patients were prescribed, but only two
specify the range at which the INR was maintained [14,
15]. Two cases of alopecia were as a result of poisoning
with warfarin [10, 12].
For heparins, where the dose has been reported it was
either given at therapeutic levels or at low doses for pre-
venting coagulation in the extracorporeal circuit (Table 1).
In a study where three groups of patients were given dif-
ferent doses of heparin, heparin and oral anticoagulant, or
heparin with an oral anticoagulant, a direct relationship
between dose and incidence of hair loss was established
[2]. In contrast, in another study a different heparin was
given to a total of 240 patients, and alopecia was not
apparently related to the total dose received [23].
The specific mechanism behind anticoagulant hair loss
caused by anticoagulants is unknown. Most studies simply
imply that telogen effluvium is part of the process. Some
groups have tried to elucidate the specific mechanism;
Kligman [8] took a biopsy of the scalp of patients who
experienced alopecia after heparin exposure. Microscopic
examination demonstrated that the capillaries of the dermis
were variably distended with blood and there was an
inconsistent, peculiar focal degeneration of collagen bun-
dles in the vicinity of vessels of the follicular connective
sheath. Flesch [24] proposed that the hair entering the
resting phase prematurely could be provoked by slow
strangling of the hair root and injury to the connective
tissue papilla. Currently there is uncertainty whether or not
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the aforementioned change in the vasculature of the scalp is
the possible cause of the injury and therefore instrumental
in the course of telogen effluvium.
Heparin is also known to possess antimitotic activity, to
increase the cohesion of the dermal–epidermal junction in
rats [25] and to suppress the proliferation of epithelial bulb
in vitro [18]. All these modalities could mediate alopecia,
and none is exclusive of the other.
4 Direct Oral Anticoagulants and Hair Loss
A literature search of Medline (1946 to present) and
Embase (1947 to present) using terms ‘alopecia’ or ‘hair
loss’ in conjunction with either ‘rivaroxaban’, ‘dabigatran,’
‘apixaban’ or ‘edoxaban’ was conducted on 15 July 2015.
Out of the three results, one was excluded as the focus of the
case report was on fibrinolysis rather than anticoagulants
and its side-effects. Of the two valid publications, one was a
poster presenting findings from the real-world Dresden
DOAC registry. At the time of publishing the poster, the
registry held 938 patients who were anticoagulated with
either dabigatran or rivaroxaban for over 3 months. During
phone follow-up, which was done at day 30 and quarterly
thereafter, 12 female patients (age range 21–99 years)
spontaneously reported hair loss. The mean treatment
duration until the onset of hair loss was 68 ± 76 days [26].
As a result, the authors calculated an alopecia incidence of
4.4 per 100 patient years. The final valid publication was a
conference abstract presenting findings of a prospective
study, which examined the value of follow-up for patients
treated with DOACs. Loizou and colleagues [27] followed
37 patients prescribed rivaroxaban (26) or dabigatran (11)
over a 12-month period. During that time patients attended
the anticoagulation clinics at 2, 4 and 26 weeks into treat-
ment where they were asked about adherence and adverse
effects. One out of the 26 patients who were prescribed
rivaroxaban had to discontinue the treatment after 2 weeks
due to tiredness and hair loss [24].
To date, WHO holds 405 reports of DOAC-associated
alopecia on VigiBase: 143 reports for rivaroxaban, 215
for dabigatran, 47 for apixaban and none thus far for
edoxaban. In the opinion of the authors, the early indica-
tions are that DOACs are implicated in this adverse effect.
5 Conclusion
The observation that both heparins and coumarins cause a
similar pattern of hair loss suggests a shared mechanism
related to their anticoagulant activity. Therefore, one pre-
dicts that alopecia will be seen as an adverse effect with the
DOACs.
The prevalence is likely to be underestimated by clini-
cians due to the latency period between drug exposure and
development of hair loss. Additionally, whether the
resulting increase in hair loss is to a clinically significant
level will depend on an individual’s baseline hair mass and
baseline daily hair loss, which is highly variable from
person to person.
Even though not formally reported in the many patients
studied in the landmark clinical trials for the DOACs,
emerging VigiBase reports and the early Dresden registry
findings suggest that DOACs are implicated. With wider-
spread clinical use of DOACs this will become clearer.
Using algorithmic methods such as Naranjo [28] would
help confirm causality, and we call on clinicians world-
wide to report alopecia suspected to be related to antico-
agulant therapy, so the scale of the problem is fully
understood.
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